Trials / Completed
CompletedNCT01234129
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
Results of Phase III Study to Assess if Zoledronic Acid Have Antumor Activity in Multiple Myeloma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 320 (actual)
- Sponsor
- Instituto Mexicano del Seguro Social · Other Government
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.
Detailed description
Assess if the use of zoledronic acid can improve outcome in patients with multiple myeloma whose are treated with cytoreductive therapy and stem cell transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | zoledronic acid | zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years |
Timeline
- Start date
- 2002-06-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2010-11-04
- Last updated
- 2010-11-04
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT01234129. Inclusion in this directory is not an endorsement.